Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARRS: Selinexor in Advanced SCC
NCT02213133Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of selinexor in head and neck squamous cell carcinoma (HNSCC), squamous cell carcinoma of the lung (LSCC) and Esophageal Squamous Cell Carcinoma (ESCC) (3 cohorts), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Disease Control Rate up to 14.6 months. Started Sep 2014; status: terminated.
02
Drugs
selinexor
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma of the lung (LSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02213133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213133.